Article Details

Sanofi Succeeding with Blue-Chip Asset, Dupixent, While Other Programs Fall Away

Retrieved on: 2021-02-05 15:33:14

Tags for this article:

Click the tags to see associated articles and topics

Sanofi Succeeding with Blue-Chip Asset, Dupixent, While Other Programs Fall Away. View article details on hiswai:

Excerpt

... indications for the monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 proteins. The company anticipates approval ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up